

Press Release

Heerlen, 4 March 2013

DSM, Corporate Communications
e-mail: media.relations@dsm.com
www.dsm.com

03E

DSM completes sale of participation in DEXPlastomers JV to Borealis

Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has completed the sale of its participation in DEXPlastomers V.o.F, a 50/50 Joint Venture of DSM with an affiliate of ExxonMobil Chemical, to Borealis. DSM also sold its LldPE Compact Solution Technology to Borealis. The transaction was announced in November 2012.

Established in 1996, DEXPlastomers is a 50/50 joint venture between DSM and Exxon Chemical Holland Ventures B.V., producing C8 plastomers and linear low density polyethylene. In the scope of the transaction are approximately 100 employees who have transferred to the new owner upon closing. DSM's LldPE Compact Solution Technology was first developed in the 1960's to produce polyethylenes in a certain density range and is instrumental to the operations of DEXPlastomers.

For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials. DSM's 50% participation in DEXPlastomers was reported under Corporate Activities in DSM's accounts.

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

Or find us on:



For more information:

DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017
fax +31 (0) 45 5740680
e-mail media.relations@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
fax +31 (0) 10 4590275
e-mail investor.relations@dsm.com

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.